Spent Under ₹10cr On Promo, Says Dolo 650 Maker

Mumbai : Micro Labs, manufacturer of Dolo 650, which is in the eye of a storm over alleged unethical practices, says it spent a minuscule amount — under Rs 10 crore per year — on the brand’s marketing and promotion.

The Bangalore-based firm, charged with distributing freebies of about Rs 1,000 crore to doctors, came under the scanner last week during a hearing in another case by the Federation of Medical and Sales Representatives Association in the Supreme Court. The Rs 2 pill became a household name for pain and fever relief during the pandemic, netting sales of Rs 362 crore for the year ended March this year — a growth of nearly 30%.

“Dolo 650 is a mega brand due to first-mover advantage, its quality, availability and reach across the country. It is a mass brand and an established market leader with 50% share, even before Covid,” Micro Labs CMD Dilip Surana told TOI, speaking for the first time on the issue.

Last month, the tax department searched the premises and conducted country-wide raids on offices of the Rs 4,500-crore Micro Labs on charges of alleged tax evasion. The company has spent Rs 1,000 crore as cumulative marketing expenditure across all brands, and not just on Dolo 650.

Executive VP (marketing) Jayaraj Govindaraju said, “On the pain relief pill alone the marketing expenditure has been typically 4-5% of its annual turnover of Rs 200-250 crore.” The basic promotions (to doctors) during Covid were of low value and included giving out free (Dolo) samples, brand reminders, masks & sanitizers, and scientific dissemination through conferences on fever, he added.

  • Related Posts

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch